In basic cytogenetic analysis 40-50% of acute myeloid leukemia (AML) patients show a normal karyotype. Karyotypically normal AML is a clinically and molecularly heterogeneous group with gene expression changes and frequently mutated genes, such as NPM1 and FLT3 (reviewed by Mrozek et al). 1 Because cytogenetic alterations in the leukemic cells are important prognostic factors determining the treatment outcome and survival of AML patients, cryptic copy number alterations could explain some of the heterogeneity. Studies using fluorescence in situ hybridization (FISH) or comparative genomic hybridization (CGH) have either not detected cryptic alterations in karyotypically normal AML or have shown them only in a few cases. 2, 3 However, these methods have limitations in resolution or genome coverage. Array-CGH (aCGH) allows genome-wide high-resolution analysis of copy number alterations that are not detectable by standard methods. Recent aCGH analyses have shown new submicroscopic copy number changes in AML with known chromosomal alterations [4] [5] [6] but aCGH studies of normal karyotypic cases have not been reported. Table 1 Clinical data, FLT3 and NPM1 mutations, and aCGH results Known exon 12 mutations in basepair (bp) location 956 including 4 bp duplication or insertions were detected.
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To detect submicroscopic copy number alterations in diagnostic samples from 26 AML patients with a normal karyotype, we used oligonucleotide CGH microarrays (44A and 44B) (Agilent Technologies, Santa Clara, CA, USA) that carry 44 000 60-mer genomic probes. The patients had been diagnosed and treated in Helsinki University Central Hospital, Finland. The clinical data are described in Table 1 and Supplementary text.
Patient DNA was extracted from bone marrow samples and reference DNA from pooled peripheral blood of healthy donors. DNA digestion, labeling, hybridization, and washing of slides were carried out according to the manufacturer's protocols (V 1.1 and 2.0). Slides were scanned using Agilent's microarray scanner G2565AA (Agilent Technologies). Microarray images were analyzed using Agilent's G2567AA Feature Extraction 8.1 software with linear and lowess normalizations and background correction. Data were analyzed using CGH Analytics software (v 3.2.32) (Agilent Technologies). In seven hybridizations, a sex mismatching reference was used to detect the level of copy number change in X and Y chromosomes, and the changes were detected in all of the cases, as expected (data not shown).
FISH validation of the aCGH findings in two cases was done as described previously 6 with LSI MYC dual color break-apart rearrangement probe (patient 16) (Vysis, Downers Grove, IL, USA) and with LSI TEL-AML1 ES dual color translocation probe (Vysis) that was applied to archival G-banding slide (patient 24). Slides were analyzed under an Axioplan 2 microscope (Carl Zeiss, Oberkochen, Germany) and images were captured using the Isis software (MetaSystems, Altlussheim, Germany). Interphases (400) and metaphases (9) were analyzed for MYC and 50 metaphases for ETV6 (TEL) and RUNX1 (AML1).
FLT3 mutations were analyzed using the FLT3 Mutation Assay kit for gel detection (in vivo Scribe Technologies, San Diego, CA, USA). The polymerase chain reaction product of NPM1 (obtained using primers NPMseqF, 5 0 -gttaactctctggtggtagaatgaa-3 0 , and NPMseqR, 5 0 -aaaaggacagccagatatcaac-3 0 , and standard protocol) was sequenced using the BigDyeTerminator kit (Applied Biosystems, Foster City, CA, USA) and ABI Prism 3130xl Genetic Analyzer (Applied Biosystems). FLT3 and NPM1 mutation data are presented in Table 1 . We detected novel cryptic copy number aberrations in 15% of AML patients with a normal karyotype at diagnosis using genome-wide oligonucleotide aCGH (Tables 1 and 2 ). The alterations were 0.4-4.1 Mb in size. Three patients had a simple molecular karyotype with one observed loss. These losses were observed in 8q24.11 (Supplementary Figure 1) , 12p12.3 ( Supplementary Figure 2) and 12p13.2 (Supplementary Figure  3) . The fourth patient (patient 16) had a more complex molecular karyotype with losses in 1q41 (Supplementary Figure  4) and 18q21.32 (Supplementary Figure 5) , gain in 3p21.3 (Supplementary Figure 6) and amplification in 8q24.13-q24.21 (Figure 1 ). Some overlaps with known polymorphisms were also detected ( Table 2 ). FLT3 mutations were detected in 54% of the analyzed cases and NPM1 mutations in 57%. Only one of the four cases with cryptic copy number alterations had mutations in FLT3 and NPM1 ( Table 1 ). The findings of cryptic alterations in mutation-negative cases are in agreement with the observation that FLT3 and NPM1 mutations are detected most often in AML cases with no cytogenetic alterations. 1 Two losses were located in 12p, a frequently altered arm in hematologic malignancies. The loss in 12p13.2 (patient 24) included ETV6 and CDKN1B ( Supplementary Figure 3a and b) that delineate the minimally deleted 12p segment in hematologic malignancies. 7 By FISH the ETV6 signal was hemizygously lost in 57% of the analyzed metaphases while RUNX1 signals were normal (Supplementary Figure 3c) . Patient 6 had a more centromeric loss in 12p12.3 showing other potential tumor suppressors ( Table 2) .
The 8q24.13-q24.21 amplicon of patient 16 (Figure 1 ) included MYC that is recurrently amplified in AML. The size of the amplicon by aCGH was 4.1 Mb and MYC was located in the center with other coamplified genes ( Table 2) . A similar region has been detected by FISH as the minimal Table 2 Cryptic alterations detected by aCGH Letters to the Editor common amplified region in AML and myelodysplastic syndrome with MYC amplification in double minute chromosomes (dmins) but, because MYC was not overexpressed, the authors suggested that it is not the target gene. 8 Rucker et al. 5 found MYC overexpressed in the amplicon but TRIB1, which was also amplified in our case, showed the highest expression.
The MYC amplification of patient 16 was visible by FISH in 80-90% of the interphase cells (at least 3-20 copies) and the signals in metaphases were seen outside the chromosomes Letters to the Editor (Figures 1c and d) . The re-evaluation of G-banding results revealed hardly visible small paired particles in some of the metaphases, which may be small dmins (Figure 1e ). Small extrachromosomal amplicons are described either as episomes (o1 Mb in size) or dmins (usually several Mb), depending on visualization under the microscope. Array CGH makes it easier to detect these small structures and reports of other amplicons in leukemia can be expected in the near future.
In conclusion, although mutations in FLT3, NPM1 or other genes are known minimal residual disease follow up-markers in karyotypically normal AML, 1 alterations detected by aCGH may also serve as markers, especially in cases where mutations are not detected. Furthermore, the altered genes, we detected using oligonucleotide aCGH may be potential oncogenes or tumor suppressors contributing to leukemogenesis.
